<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04613752</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190988</org_study_id>
    <nct_id>NCT04613752</nct_id>
  </id_info>
  <brief_title>Diaphragm Dysfunction in ARDS Patients With V-V ECMO</brief_title>
  <acronym>DD-ECMO</acronym>
  <official_title>Evaluation and Follow up of Diaphragm Function in Acute Respiratory Distress Syndrome Patients With Veino-venous Extracorporeal Oxygenation Membrane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of veno-venous extracorporeal oxygenation membrane is a therapeutic option for the&#xD;
      management of the most severe patients with acute respiratory distress syndrome (ARDS).&#xD;
&#xD;
      Given the prolonged duration of this strategy, the question of its impact on the occurrence&#xD;
      on diaphragm dysfunction has been raised. The present study endeavors to evaluate and follow&#xD;
      up the prevalence, risk factors and prognosis of diaphragm dysfunction in patients with&#xD;
      VV-ECMO.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Use of veno-venous extracorporeal oxygenation membrane is a therapeutic option for the&#xD;
      management of the most severe patients with acute respiratory distress syndrome (ARDS). It&#xD;
      allows to provide a protective lung ventilation by reducing the level of airway pressures&#xD;
      generated by the ventilator. The objective is to minimize the harmful effects of mechanical&#xD;
      ventilation in the lungs and to provide adequate gases exchanges. This strategy requires a&#xD;
      deep sedation to allow a perfect synchrony between the patient and the ventilator. Such a&#xD;
      synchrony puts the respiratory muscles - in particular the diaphragm - completely at rest.&#xD;
&#xD;
      Given the prolonged duration of this strategy, the question of its impact on the occurrence&#xD;
      on diaphragm dysfunction has been raised. Such a dysfunction has been associated with&#xD;
      prolonged duration of mechanical ventilation and poor outcomes but its effect in patients&#xD;
      with veno-venous extracorporeal oxygenation membrane has never been evaluated so far.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">July 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 5, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diaphragm function</measure>
    <time_frame>until day 28</time_frame>
    <description>as defined by the pressure generating capacity of the diaphragm &lt; 11 cmH2O</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of ECMO</measure>
    <time_frame>until day 60</time_frame>
    <description>from inclusion until ECMO removal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of invasive mechanical ventilation</measure>
    <time_frame>until day 60</time_frame>
    <description>from inclusion until extubation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single experimental group in which diaphragmatic function measurements and diaphragmatic ultrasound will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>diaphragmatic function measurements and diaphragmatic ultrasound</intervention_name>
    <description>A single experimental group in which diaphragmatic function measurements and diaphragmatic ultrasound will be performed.</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt; 18 years&#xD;
&#xD;
          -  ARDS according to the Berlin definition&#xD;
&#xD;
          -  V-V ECMO&#xD;
&#xD;
          -  patient or next of kin agrees to participate&#xD;
&#xD;
          -  patient with health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  Opposition to participate&#xD;
&#xD;
          -  Contra indications to the phrenic nerves stimulation technique (pace maker,&#xD;
             pneumothorax)&quot;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Dres</last_name>
    <role>Study Chair</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Dres</last_name>
    <phone>33142167809</phone>
    <email>martin.dres@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Dres, MCU-PH</last_name>
      <phone>0142167761</phone>
      <email>martin.dres@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARDS</keyword>
  <keyword>ECMO</keyword>
  <keyword>diaphragm function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

